Literature DB >> 15570299

Clinical variability of patients with the t(6;8)(q27;p12) and FGFR1OP-FGFR1 fusion: two further cases.

José L Vizmanos1, Roberto Hernández, María J Vidal, María J Larráyoz, María D Odero, Julián Marín, María T Ardanaz, María J Calasanz, Nicholas C P Cross.   

Abstract

We report two new cases with the t(6;8)(q27;p12) and FGFR1OP-FGFR1 fusion. Case 1 presented with polycythaemia vera (PV) and evolved over 4 years to a myeloproliferative disorder (MPD) resembling the 8p11 myeloproliferative syndrome (EMS). Case 2 presented with B-cell lymphoblastic leukaemia (B-ALL). These cases illustrate the clinical heterogeneity observed in patients with FGFR1 rearrangements and suggest that constitutively activated tyrosine kinases may be more widespread in MPDs.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15570299     DOI： 10.1038/sj.thj.6200561

Source DB:  PubMed          Journal:  Hematol J        ISSN： 1466-4860


  9 in total

1.  A complex of two centrosomal proteins, CAP350 and FOP, cooperates with EB1 in microtubule anchoring.

Authors:  Xiumin Yan; Robert Habedanck; Erich A Nigg
Journal:  Mol Biol Cell       Date:  2005-11-28       Impact factor: 4.138

2.  Diagnostic application of next-generation sequencing in ZMYM2-FGFR1 8p11 myeloproliferative syndrome: A case report.

Authors:  Yadan Wang; Xiaofei Wu; Jun Deng; Hao Yu; Ren Xu; Zhiyi Zhu; Shichun Tu; Yu Hu
Journal:  Cancer Biol Ther       Date:  2016-08-02       Impact factor: 4.742

3.  Cytogenetically cryptic ZMYM2-FLT3 and DIAPH1-PDGFRB gene fusions in myeloid neoplasms with eosinophilia.

Authors:  M Jawhar; N Naumann; M Knut; J Score; M Ghazzawi; B Schneider; K-A Kreuzer; M Hallek; H G Drexler; J Chacko; L Wallis; A Fabarius; G Metzgeroth; W-K Hofmann; A Chase; W Tapper; A Reiter; N C P Cross
Journal:  Leukemia       Date:  2017-07-28       Impact factor: 11.528

4.  A novel chromosomal abnormality, t(6;10)(q27;q22), found in a polycythemic potential donor for allogeneic hematopoietic stem cell transplantation.

Authors:  Hideki Mitsui; Norimitsu Saito; Atsushi Satake; Tsuyoshi Nakazawa; Takahiro Karasuno; Akira Hiraoka
Journal:  Int J Hematol       Date:  2005-07       Impact factor: 2.490

5.  Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders.

Authors:  C Walz; N C P Cross; R A Van Etten; A Reiter
Journal:  Leukemia       Date:  2008-06-05       Impact factor: 11.528

Review 6.  BCR-ABL-negative chronic myeloid leukemia.

Authors:  Sonja Burgstaller; Andreas Reiter; Nicholas C P Cross
Journal:  Curr Hematol Malig Rep       Date:  2007-05       Impact factor: 4.213

Review 7.  Functional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancers.

Authors:  Kai Hung Tiong; Li Yen Mah; Chee-Onn Leong
Journal:  Apoptosis       Date:  2013-12       Impact factor: 4.677

Review 8.  [Myeloid/lymphoid neoplasms with eosinophilia and FGFR1 rearrangement: 5 cases report and literatures review].

Authors:  Y T Liu; J W Zhao; J Feng; Q H Li; Y M Chen; L G Qiu; Z J Xiao; Y Li; B F Gong; X Y Gong; Y C Mi; J X Wang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2019-10-14

9.  Serious neonatal morbidities are associated with differences in DNA methylation among very preterm infants.

Authors:  Todd M Everson; T Michael O'Shea; Amber Burt; Karen Hermetz; Brian S Carter; Jennifer Helderman; Julie A Hofheimer; Elisabeth C McGowan; Charles R Neal; Steven L Pastyrnak; Lynne M Smith; Antoine Soliman; Sheri A DellaGrotta; Lynne M Dansereau; James F Padbury; Barry M Lester; Carmen J Marsit
Journal:  Clin Epigenetics       Date:  2020-10-19       Impact factor: 7.259
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.